MYRIAD GENETICS INC (MYGN)
Health Care · Genetic Testing and Molecular Diagnostics · NASDAQ
Myriad Genetics is a genetic testing company focused on providing actionable insights for cancer risk, reproductive health, and mental health clinical decisions.
What MYRIAD GENETICS INC does
Myriad Genetics is a genetic testing and precision medicine company that develops and markets tests for cancer, reproductive health, and mental health. The company provides molecular diagnostic tests that help inform clinical decision-making across various stages of patient care.
Themes: precision medicine, genetic testing, cancer diagnostics, reproductive health, pharmacogenomics
Fundamentals
- Price$5.54 as of 2026-10-20 close
- Market cap$530M as of 2026-07-28 (share count; price 2026-10-20)
- 1-year return-29.9% 2025-10-20 close $7.90 → 2026-10-20 close $5.54
- P/En/a negative earnings
- Net margin-44.4% FY2025, SEC XBRL
- Gross margin+69.9% FY2025, SEC XBRL
- ROE-99.4% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equity0.40 borrowings, leases excluded / equity — 10-Q/10-K balance sheet 2026-06-30
- Revenue growth (YoY)-1.6% FY2025, SEC XBRL
- Revenue CAGR (3y)+6.7% SEC XBRL
- Beta1.14 as of 2026-09-03
- Last reported earnings2026-07-30 SEC EDGAR Form 8-K (Item 2.02)
How MYGN compares in its sector
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-03
- gross marginmiddle range 189 covered Health Care peers, as of 2026-09-03
- return on equitybottom 25% 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Revenue | Gross profit | Operating income | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $191M | $127M | -$39M | -$43M | -$0.46 | -$8M† |
| Q1 FY2026 2026-03-31 | $200M | $138M | -$31M | -$34M | -$0.36 | -$16M |
| Q4 FY2025 2025-12-31 | $210M† | $147M† | -$6M† | -$8M† | -$0.07† | $11M† |
| Q3 FY2025 2025-09-30 | $206M | $144M | -$23M | -$27M | -$0.29 | $21M† |
| Q2 FY2025 2025-06-30 | $213M | $152M | -$329M | -$331M | -$3.57 | -$14M† |
| Q1 FY2025 2025-03-31 | $196M | $134M | -$29M | -$100000 | $0.00 | -$16M |
| Q4 FY2024 2024-12-31 | $211M† | $151M† | -$39M† | -$43M† | -$0.47† | $7M† |
| Q3 FY2024 2024-09-30 | $213M | $150M | -$20M | -$22M | -$0.24 | $700000† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$115M
- Total debt$121M borrowings only; leases excluded
- Net debt$6M total debt − cash − short-term investments
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How MYRIAD GENETICS INC looks technically
MYRIAD GENETICS INC (MYGN) is trading 19.5% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed below its 200-day average about 168 trading days ago — a "death cross", a bearish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 35, with buyers in control. Momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 72, in overbought territory (above 70). MACD, a trend-momentum gauge, turned bullish about 1 trading day ago (its momentum flipped positive). It just made a new 20-day high, its first since 2026-07-24, pushing above its recent trading range. It is 35.5% below its highest point of the past year. Trading volume is running unusually high — about 11.8× its 30-day average, a sign of heightened interest.
Trend
9
| Distance from the 200-day | it is trading 19.5% above its 200-day average, the long-term trend line — a longer-term uptrend | +19.5% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $3.73 | $3.73 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $4.64 | $4.64 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 14 calendar days ago — the swings before that are what the structure reading is measured on | 14 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that upward direction; the labelling fails if price closes below 3.295. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible upward five-wave sequence, in wave 4 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 168 trading days ago — a "death cross", a bearish long-term signal | 168 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 19.5% above | +19.5% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 35, with buyers in control | 35.3 |
Momentum
3
| 14-day RSI | momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 72, in overbought territory (above 70) | 72.3 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($3.95 to $5.95) — its "stochastic" reading is 80 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 79.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 1 trading day ago (its momentum flipped positive) | 1 session |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $8.59 | $8.59 |
|---|---|---|
| From the 52-week high | it is 35.5% below its 52-week high (its highest price of the past year) | -35.5% |
| Above the 52-week low | it is 102.2% above its 52-week low (its lowest price of the past year) | +102.2% |
| Below the 52-week high | it is 35.5% below its highest point of the past year | 35.5% |
| Since a 20-day breakout | it just made a new 20-day high, its first since 2026-07-24, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day high, its first since 2026-07-24, pushing above its recent trading range | 1 session |
| All-time high | its highest closing price on record is $50.44 (set on 2018-09-04) | $50.44 |
| Given back of the 52-week move | over the past year its closes ranged ($2.86 to $8.18), and it has recovered around half of its fall from last year’s high — 50% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $6.15 to $6.32. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 50.4% |
| From the all-time high | it is 89.0% below its all-time high | -89.0% |
| Nearest price level | it is trading 2.9% above a support level at $5.38 — a price it turned at twice since 2025-06-04, most recently on 2026-04-15. Since 2024-10-21 it has 6 such levels below the current price and 5 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -2.9% |
| All-time low | its lowest closing price on record is $2.74 (set on 2026-08-03) | $2.74 |
| Above the all-time low | it is 102.2% above its all-time low | +102.2% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 41st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.3736 between its high and its low — about 6.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.3736 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $3.65 and $4.94 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $3.65 – $4.29 – $4.94 |
| Typical daily range (% of price) | its price moves about 6.7% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.7% |
| Stretch from the 200-day average | it is trading 2.4 daily ranges above its 200-day average price (19.5% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.4 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is running unusually high — about 11.8× its 30-day average, a sign of heightened interest | 11.85× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 1.5% since the prior reading | +1.5% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a bullish engulfing | 7 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 7 sessions ago |
|---|---|---|
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-20 26.8% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +26.8% |
|---|---|---|
| Open gap | it gapped 26.8% above the previous close today and has not traded back through the level it left behind at 4.21 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +26.8% |
| Gap filled | a 2.5% gap up opened on 2026-10-02 has been "filled" 8 sessions ago — price traded back through the level the gap left behind, and it took 4 sessions to close | 8 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +39.2% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 41.5 percentage points (the stock gained 42.4% while the market gained 1.0%) | +41.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 10.1 percentage points (the stock lost 6.4% while the market gained 3.6%) | -10.1% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 0.7 percentage points (the stock gained 7.8% while the market gained 8.5%) | -0.7% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 44.4 percentage points (the stock lost 29.9% while the market gained 14.6%) | -44.4% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, a strong uptrend, with buyers in control, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, its RSI momentum gauge is overbought (a stretched reading), lagging the market over 6 months — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 21% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 22.2% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +21.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 25% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $4.44 — a volume-weighted average of daily closes over 199 sessions, not a true tick-by-tick VWAP. | +24.8% |
|---|---|---|
| Vs the average paid since it last reported | the price is 43% above the average price paid since it last reported on 2026-07-30 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $3.87 — a volume-weighted average of daily closes over 58 sessions, not a true tick-by-tick VWAP. | +43.2% |
Price levels it has turned at before
MYGN last closed at $5.54 on 2026-10-20. Since 2024-10-21 it has turned at 6 prices below its last close and 5 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $5.38 | Support | 2.9% below the last close | turned there twice · 2025-06-04 to 2026-04-15 |
| $5.71 | Resistance | 3.0% above the last close | turned there three times · 2025-07-01 to 2026-07-13 |
| $4.79 | Support | 13.6% below the last close | turned there three times · 2025-06-23 to 2026-10-06 |
| $4.53 | Support | 18.3% below the last close | turned there twice · 2025-05-20 to 2026-04-23 |
| $7.37 | Resistance | 33.1% above the last close | turned there three times · 2025-04-09 to 2025-12-11 |
| $8.54 | Resistance | 54.2% above the last close | turned there twice · 2025-10-16 to 2025-10-27 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes below $3.29.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
On past moves of this shape the leg has usually ended somewhere between $3.88 and $4.38 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This reading has stood for 6 trading days, since 2026-10-13.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Trading above the 50-day moving average · Tested and reclaimed 200-day support · Overbought (14-day RSI above 70) · Pulled back from the 12-month high · Unusually heavy trading volume | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingHold (3.22 mean, 1=Strong Buy…5=Strong Sell) — 8 analysts
- Mean price target$4.11 range $2.00 – $8.00; median $3.85
Analyst estimates, as of 2026-10-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for MYGN
- Consensus EPS estimate-$0.1996 next reporting period, as of 2026-10-17
- Estimate change, 30 days+$0.00783 from -$0.2074, on 2026-09-12, 35-day window
- Readings revised upward29% of 7 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["History of net losses and accumulated deficit.","Dependence on accurate and timely performance of laboratory operations.","Regulatory uncertainty in the genetic testing and healthcare diagnostic space."]
What changed in the latest 10-Q
AI-assisted comparison of MYGN's 10-Q filed 2026-05-06 against the prior one filed 2025-11-04.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing references audited Consolidated Financial Statements for year ended December 31, 2025 (filed 2026-05-06)
- Newer filing references Form 10-K filed February 24, 2026 (filed 2026-05-06)
- Newer filing adds 'MyChoice' (capitalized) to trademark list (filed 2026-05-06)
- Newer filing adds 'partnerships' to risk factor about obtaining corporate partnerships and collaborations (filed 2026-05-06)
- Newer filing removes specific reference to UnitedHealthcare coverage decision for GeneSight test from risk factors (filed 2026-05-06)
- Removed:
- Older filing references audited Consolidated Financial Statements for year ended December 31, 2024 (filed 2025-11-04)
- Older filing references Form 10-K filed February 28, 2025 (filed 2025-11-04)
- Older filing references Form 10-Q filings from May 7, 2025 and August 6, 2025 as updates to Risk Factors (filed 2025-11-04)
- Older filing includes specific risk regarding 'UnitedHealthcare's coverage decisions not to provide coverage for certain multi-gene panel pharmacogenetic tests, including our GeneSight test' (filed 2025-11-04)
- Older filing describes company as 'molecular diagnostic testing and precision company' (filed 2025-11-04)
- Reworded:
- Risk factor wording changed from 'risks related to recent changes in the our senior management team and the successful implantation of the company's strategic plan' to 'risks related to recent changes in our senior management team and the successful implementation of our strategic plan' (grammatical corrections) (filed 2026-05-06)
- Risk factor wording changed from 'risks related to our ability to obtain new corporate collaborations or licenses' to 'risks related to our ability to obtain new corporate partnerships and collaborations or licenses' (filed 2026-05-06)
- Risk factor reordered: 'the risk that we are not able to secure additional financing...' moved from earlier position to later position in list (filed 2026-05-06)
- Company description changed from 'We are a leading molecular diagnostic testing and precision company dedicated to advancing health and well-being for all' to 'Myriad Genetics is a leading molecular diagnostics and precision medicine company committed to advancing health and well-being for all' (filed 2026-05-06)
- Wording change in General section from 'We develop and offer molecular tests' to 'We develop and commercialize molecular tests' (filed 2026-05-06)
- Notes:
- Newer filing text appears truncated at end of General section; older filing text also truncated; full comparison of General section not possible
- Trademark list in newer filing shows 'MyChoice' while older shows 'myChoice' (capitalization difference)
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 5 days since 2026-10-16 have not been checked yet.
- Last 180 days · read to 2026-10-161 buy ($27638) · 1 sell ($66843) — 1 buying, 1 selling insiders
Most recent open-market transaction: 2026-06-08. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about MYGN's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding MYGN as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 19,819,685
- Reported value $113,170,398
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 0 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about MYGN's institutional holders → See what each manager we track holds →
Short interest (FINRA)
MYGN had 8,546,169 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
MYGN had 8.93% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.25 days to cover at the same settlement.
- Reported short interest (shares) 8,546,169
- Short interest (% of shares outstanding) 8.93%
- Prior settlement (shares) 9,345,601
- Reported change -8.55%
- Days to cover (reported) 4.25
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Exact Sciences (EXAS)
- Illumina (ILMN)
- Natera (NTRA)
- Laboratory Corporation of America (LH)
- Quest Diagnostics (DGX)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare MYGN vs…
MYRIAD GENETICS INC is found in…
Frequently asked questions
What does MYRIAD GENETICS INC (MYGN) do?
Myriad Genetics is a genetic testing and precision medicine company that develops and markets tests for cancer, reproductive health, and mental health. The company provides molecular diagnostic tests that help inform clinical decision-making across various stages of patient care.
What sector is MYRIAD GENETICS INC (MYGN) in?
MYRIAD GENETICS INC (MYGN) is classified in the Health Care sector. Its industry is Genetic Testing and Molecular Diagnostics. It trades on NASDAQ.
Who are MYRIAD GENETICS INC's (MYGN) competitors?
Notable peers of MYRIAD GENETICS INC (MYGN) include Exact Sciences, Illumina, Natera, Laboratory Corporation of America and Quest Diagnostics. This peer set is informational only — not financial advice.
Is MYRIAD GENETICS INC (MYGN) overbought or oversold right now?
MYRIAD GENETICS INC (MYGN) is currently in overbought territory (its 14-day RSI is 72, above 70) (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on MYGN come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.